Skip to main content
. 2022 Nov 9;12:1059253. doi: 10.3389/fonc.2022.1059253

Figure 2.

Figure 2

The role of CAFs in affecting lung cancer biological pathways and immunotherapy response. (A) The GSEA analysis between high- and low-CAFs groups based on the Hallmark gene set; (B) The GSEA analysis between high- and low-CAFs groups based on the GO gene set; (C) Correlation analysis between TIDE score and CAFs score; (D) CAFs level in immunotherapy responders and non-responders ***P < 0.001; (E) Percentage of immunotherapy responders in patients with high and low CAFs infiltration, *P < 0.05.